Alpacas present a potential cure for cancer
Sometimes the answers to unsolved medical problems lie in the most unusual of places. This time, a solution to cancer has come about from the immune system of camelids.
A collaborative study by the Institute for Research in Biomedicine (IRB Barcelona) and the Vrije Universiteit Brussel (VUB), in Belgium, describes a number of therapeutic tools that have the capacity to block the activity of Epidermal Growth Factor (EGF), a growth factor that is dysregulated in cancer cells.
EGF is often a target in the treatment of cancer; however, no inhibitors have been found for it to date. The team of researchers have identified a family of nanobodies – antibodies that are exclusive to camelids – derived from alpacas that are effective against EGF. They describe the molecular mechanisms underlying the affinity and selectivity of these nanobodies in an article published in the scientific journal Angewandte Chemie.
“In spite of advances in treatments against the EGR receptor (EGFR) in patients, their efficacy decreases over time because patients develop resistance,” explain Monica Varese and Salvador Guardiola, co-authors of the study and postdoctoral researchers at IRB Barcelona.
“By taking advantage of an emerging biotech tool, nanobodies, we have been able to synthesise the first inhibitors with high affinity for EGF,”
IRB Barcelona produced the EGF protein and their Belgian colleagues administered it to alpacas. The immune response of these animals to the foreign antigen produced a series of nanobodies, and the researchers identified a family of these molecules as potential inhibitors of EGF. The IRB Barcelona team, which has extensive expertise in molecular recognition between proteins, observed that some of the ligands showed high affinity and selectivity towards EGF, and, using a range of biophysical techniques, they characterised the interactions in cells in vitro and in human cancer cells.
“By injecting EGF into the alpaca we have challenged nature to find a molecule capable of binding tightly and with high selectivity to EGF, and it has come up with two very different but equally effective solutions for such a small and difficult antigen as EGF,” says Ernest Giralt, head of the Peptide and Proteins Lab at IRB Barcelona and senior professor at the University of Barcelona.
These drugs could be useful for patients who develop resistance to the EGFR inhibitors that are currently available. The first step is now to evaluate the pharmacological effect of these new nanobodies in cell and animal models of cancer.
